FORMYCON AG (FYB.DE) Fundamental Analysis & Valuation

FRA:FYB • DE000A1EWVY8

19.87 EUR
+0.19 (+0.97%)
Last: Mar 6, 2026, 02:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This FYB.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, FYB scores 3 out of 10 in our fundamental rating. FYB was compared to 75 industry peers in the Biotechnology industry. Both the profitability and financial health of FYB have multiple concerns. FYB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. FYB.DE Profitability Analysis

1.1 Basic Checks

  • In the past year FYB has reported negative net income.
  • FYB had a positive operating cash flow in the past year.
  • In multiple years FYB reported negative net income over the last 5 years.
  • FYB had a negative operating cash flow in each of the past 5 years.
FYB.DE Yearly Net Income VS EBIT VS OCF VS FCFFYB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • FYB has a Return On Assets of -22.86%. This is comparable to the rest of the industry: FYB outperforms 58.67% of its industry peers.
  • FYB has a Return On Equity of -41.58%. This is in the better half of the industry: FYB outperforms 64.00% of its industry peers.
Industry RankSector Rank
ROA -22.86%
ROE -41.58%
ROIC N/A
ROA(3y)-1.19%
ROA(5y)-6.14%
ROE(3y)-0.68%
ROE(5y)-7.18%
ROIC(3y)N/A
ROIC(5y)N/A
FYB.DE Yearly ROA, ROE, ROICFYB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FYB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FYB.DE Yearly Profit, Operating, Gross MarginsFYB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. FYB.DE Health Analysis

2.1 Basic Checks

  • FYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, FYB has more shares outstanding
  • The number of shares outstanding for FYB has been increased compared to 5 years ago.
  • FYB has a better debt/assets ratio than last year.
FYB.DE Yearly Shares OutstandingFYB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
FYB.DE Yearly Total Debt VS Total AssetsFYB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • FYB has an Altman-Z score of 0.37. This is a bad value and indicates that FYB is not financially healthy and even has some risk of bankruptcy.
  • FYB has a Altman-Z score of 0.37. This is comparable to the rest of the industry: FYB outperforms 56.00% of its industry peers.
  • FYB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • FYB has a better Debt to Equity ratio (0.02) than 78.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 0.37
ROIC/WACCN/A
WACC7.23%
FYB.DE Yearly LT Debt VS Equity VS FCFFYB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that FYB should not have too much problems paying its short term obligations.
  • FYB has a Current ratio of 1.54. This is comparable to the rest of the industry: FYB outperforms 41.33% of its industry peers.
  • FYB has a Quick Ratio of 1.51. This is a normal value and indicates that FYB is financially healthy and should not expect problems in meeting its short term obligations.
  • FYB has a Quick ratio (1.51) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.51
FYB.DE Yearly Current Assets VS Current LiabilitesFYB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. FYB.DE Growth Analysis

3.1 Past

  • The earnings per share for FYB have decreased strongly by -339.98% in the last year.
  • Looking at the last year, FYB shows a very negative growth in Revenue. The Revenue has decreased by -14.84% in the last year.
  • FYB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.48% yearly.
EPS 1Y (TTM)-339.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425.42%
Revenue 1Y (TTM)-14.84%
Revenue growth 3Y23.92%
Revenue growth 5Y15.48%
Sales Q2Q%0.03%

3.2 Future

  • Based on estimates for the next years, FYB will show a very strong growth in Earnings Per Share. The EPS will grow by 48.97% on average per year.
  • Based on estimates for the next years, FYB will show a very strong growth in Revenue. The Revenue will grow by 21.06% on average per year.
EPS Next Y-42.25%
EPS Next 2Y39.02%
EPS Next 3Y48.97%
EPS Next 5YN/A
Revenue Next Year-9.62%
Revenue Next 2Y19.01%
Revenue Next 3Y25.28%
Revenue Next 5Y21.06%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FYB.DE Yearly Revenue VS EstimatesFYB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
FYB.DE Yearly EPS VS EstimatesFYB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

2

4. FYB.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FYB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FYB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FYB.DE Price Earnings VS Forward Price EarningsFYB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

  • 96.00% of the companies in the same industry are more expensive than FYB, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.89
FYB.DE Per share dataFYB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as FYB's earnings are expected to grow with 48.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.02%
EPS Next 3Y48.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FYB.DE Dividend Analysis

5.1 Amount

  • No dividends for FYB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FYB.DE Fundamentals: All Metrics, Ratios and Statistics

FORMYCON AG

FRA:FYB (3/6/2026, 2:04:41 PM)

19.87

+0.19 (+0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners7.65%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap351.10M
Revenue(TTM)51.78M
Net Income(TTM)-169.77M
Analysts83.08
Price Target51.87 (161.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.28%
Min Revenue beat(2)-63.69%
Max Revenue beat(2)90.24%
Revenue beat(4)2
Avg Revenue beat(4)18.75%
Min Revenue beat(4)-63.69%
Max Revenue beat(4)90.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.86%
PT rev (3m)-1.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)36.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-1.76%
Revenue NY rev (3m)-1.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.78
P/FCF N/A
P/OCF 23.78
P/B 0.86
P/tB N/A
EV/EBITDA 2.89
EPS(TTM)-9.6
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)0.84
OCFY4.2%
SpS2.93
BVpS23.11
TBVpS-2.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.86%
ROE -41.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1.19%
ROA(5y)-6.14%
ROE(3y)-0.68%
ROE(5y)-7.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.08
Cap/Depr 24.47%
Cap/Sales 71.59%
Interest Coverage N/A
Cash Conversion 12.89%
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.51
Altman-Z 0.37
F-Score3
WACC7.23%
ROIC/WACCN/A
Cap/Depr(3y)860.64%
Cap/Depr(5y)536.06%
Cap/Sales(3y)44.41%
Cap/Sales(5y)27.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-339.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425.42%
EPS Next Y-42.25%
EPS Next 2Y39.02%
EPS Next 3Y48.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.84%
Revenue growth 3Y23.92%
Revenue growth 5Y15.48%
Sales Q2Q%0.03%
Revenue Next Year-9.62%
Revenue Next 2Y19.01%
Revenue Next 3Y25.28%
Revenue Next 5Y21.06%
EBIT growth 1Y-49.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-104.1%
EBIT Next 3Y92.98%
EBIT Next 5Y71.25%
FCF growth 1Y58.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.39%
OCF growth 3YN/A
OCF growth 5YN/A

FORMYCON AG / FYB.DE FAQ

What is the ChartMill fundamental rating of FORMYCON AG (FYB.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to FYB.DE.


What is the valuation status of FORMYCON AG (FYB.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to FORMYCON AG (FYB.DE). This can be considered as Overvalued.


What is the profitability of FYB stock?

FORMYCON AG (FYB.DE) has a profitability rating of 1 / 10.


How financially healthy is FORMYCON AG?

The financial health rating of FORMYCON AG (FYB.DE) is 3 / 10.


Can you provide the expected EPS growth for FYB stock?

The Earnings per Share (EPS) of FORMYCON AG (FYB.DE) is expected to decline by -42.25% in the next year.